Findings promising for PET imaging agent flutemetamol

04/26/2012 | (free registration)

Findings from four pooled studies of brain biopsies showed the experimental PET imaging agent F-18 flutemetamol to have 93% sensitivity and 100% specificity in detecting beta amyloid plaque, which has been linked to Alzheimer's disease. Results of a brain autopsy study showed the agent diagnosed amyloid with an 86% sensitivity and 92% specificity.

View Full Article in: (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
San Jose, CA
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Teaching Associate (Hospitality Management)
University of Illinois at Urbana-Champaign
Urbana, IL
Director, Global Regulatory Affairs
Rodan and Fields, LLC
San Francisco, CA